IQVIA today announced the Japan and Asia Pacific (JAPAC) expansion of IQVIA Biotech, a tailored approach to deliver integrated clinical and commercial solutions for biotech and emerging biopharma companies, a company release said.
“Biotech companies are fuelling rapid development of biologics, drugs and vaccines, and when they succeed, we all succeed. By launching IQVIA Biotech in JAPAC, we can support the aspirations of biotech customers with agile solutions and resources dedicated to support smaller companies,” said Richard Staub, President – Research and Development Solutions, IQVIA.”
Launched in North America and Europe in early 2019, IQVIA Biotech was designed in response to the needs of biotech customers for transparent and fit-for-purpose clinical processes with dedicated and therapeutically-aligned partners. Since its launch, IQVIA Biotech has initiated hundreds of new trials for biotech companies, including COVID-19 trials.
The dedicated IQVIA Biotech teams in JAPAC are equipped to meet the needs of biotech customers by creating intelligent connections across the drug development process.
Dr Senthil Sockalingam, Head, IQVIA Biotech, JAPAC and Chief Medical Officer (CMO), APAC, said, “Biotech companies have increasing global aspirations, and demand is also growing from global emerging customers for delivery in this region. IQVIA Biotech allows us to offer customers a truly seamless experience fully aligned with flexible and tailored integrated solutions delivered by specialised teams.”